In a comprehensive survey of the available preclinical literature, we searched the literature using the key words “ELN”, “FLT3”, “NPM1”, “DEK-NUP214”, “KMT2A”, “BCR-ABL1”, “GATA2”, “MECOM”, “EVI1”, “RUNX1”, “ASXL1”, “TP53”, “complex karyotype”, “menin”, and “anti-cd47 antibody” with the necessary key word “AML”. This evidence concerns the gene RUNX1 and acute myeloid leukemia.